On August 17, GENSCRIPT BIO rose 3.3% in regular trading, trading at HK$25.92/share, with turnover of HK$150 million. The rally was driven by the company's interim results released on August 16, which significantly exceeded market expectations across key financial metrics.

For the six months ended June 30, GENSCRIPT BIO reported revenue of approximately US$404 million, representing a 27.3% year-over-year increase. Gross profit reached US$207 million, up 48.0% YoY, benefiting from business mix optimization and improved capacity utilization. Adjusted operating profit surged 102.8% to approximately US$94 million, while adjusted net profit jumped 203.3% to US$62.5 million. Core business net profit doubled to US$25.6 million from US$11.8 million in the prior period.

Management attributed the strong growth to surging AI-driven drug discovery demand, robust upstream CRDMO recovery driving higher project intake and capacity utilization, and continued expansion in the industrial enzymes segment. AIDD-related business doubled year-over-year, marking three consecutive half-year periods of rapid growth. Meanwhile, associate Legend Biotech reported CARVYKTI Q2 net trade sales of US$657 million, up 49.4% YoY.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)